Stratec Se

Stratec Se ROE

The Return on Equity (ROE) of Stratec Se (SBS.DE) as of Oct 15, 2026 is -0.10 %. In the previous year, Return on Equity (ROE) was 6.61 % — a change of -101.54% (lower).

ROE

-0.10 %

YoY

-101.54%

Last updated:

In 2025, Stratec Se's return on equity (ROE) was -0.10 %, a -101.54% increase from the 6.61 % ROE in the previous year.

The Stratec Se ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2018
5.89 EUR
Jan 1, 2019
9.08 EUR
Jan 1, 2020
14.59 EUR
Jan 1, 2021
19.42 EUR
Jan 1, 2022
12.98 EUR
Jan 1, 2023
6.59 EUR
Jan 1, 2024
6.61 EUR
Jan 1, 2025
-0.10 EUR
The Stratec Se ROE history
YEARROEYoY
-0.10 %-101.54%
6.61 %+0.28%
6.59 %-49.24%
12.98 %-33.17%
19.42 %+33.10%
14.59 %+60.66%
9.08 %+54.11%
5.89 %-63.72%
16.24 %+19.26%
13.62 %-19.66%
16.95 %-3.92%
17.64 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Stratec Se Stock analysis

What does Stratec Se do? The company Stratec SE is a German company operating in the medical technology industry. It was founded in 1984 and has since become a leading provider of automation solutions and diagnostic instruments. Stratec's business model is based on the development and production of devices and systems used in medical diagnostics. The company focuses in particular on the areas of immunology, clinical chemistry, and hematology. Stratec also offers innovative solutions in microscopy and cell analysis. In the "automation solutions" division, Stratec develops systems for the automation of laboratory processes. These are mainly used in clinical diagnostics to accelerate and simplify workflow. Examples include sample identification systems, pipetting robots, and analysis devices. In the "in vitro diagnostics" division, Stratec offers products for determining blood values. This includes devices for determining glucose, cholesterol, and hemoglobin levels, as well as devices for infection diagnostics and tumor and allergy diagnostics. Another division of Stratec is "microscopy." The company manufactures automated microscope systems, primarily used in biomedical research to analyze cells and tissues. In the "cell analysis" division, Stratec offers innovative methods for analyzing cells, such as cell growth and vitality determination. Stratec always focuses on tailoring the design of its products to the needs of its customers. High flexibility in device development and manufacturing is therefore an important factor in the company's success. In addition to device development and production, Stratec also provides services related to its products. These include installation, maintenance, and on-site repair of devices for customers. Stratec SE operates internationally and has branches in Europe, Asia, and America. The company employs over 1,000 people worldwide. Overall, Stratec SE is a successful and renowned provider of medical devices and systems for automating laboratory processes. With its diverse product portfolio and high flexibility in customer support, Stratec has earned a leading position in the industry. Stratec Se is one of the most popular companies on Eulerpool.

ROE Details

Decoding Stratec Se's Return on Equity (ROE)

Stratec Se's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Stratec Se's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Stratec Se's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Stratec Se’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Stratec Se stock

Return on Equity (ROE) of Stratec Se is -0.10 % in 2025.

Return on Equity (ROE) of Stratec Se changed from 6.61 % to -0.10 %, representing a -101.54% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Stratec Se since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Stratec Se with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Stratec Se

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Stratec Se